



ALZHEIMER'S CURE CHARITY TOKEN **WHITEPAPER**

GETTING RESULTS NOW IN DECENTRALIZED SCIENCE.
ONE TOKEN TO RULE THEM ALL



TABLE OF CONTENTS

EXECUTIVE SUMMARY	04
ALZHEIMER'S CURE CHARITY TOKEN - AN INTRODUCTION	05
MISSION	06
VISION	06
ALZHEIMER'S CURE CHARITY TOKEN ECOSYSTEM.....	07
Our Approach in Curing Neurodegenerative Diseases	07
Harnessing Yamanaka Factors for Regenerative Therapy	07
Unlocking the Power of Epigenetics	08
Targeted Diseases: A Mission to Restore Brain Health	08
Research and Development	
Advancing Towards Breakthrough Therapies	09
Current Progress in Preclinical Research	09
The Cure - The Native Utility Token	09
Token Utilities	10
A Deflationary Token Burning Mechanism	10
Token Burn Mechanism	10
Daily Sell Limits for Stability	11
Donations: Directly Supporting Breakthrough Research	11
How Donations Work?	11
THE FUTURE SCOPE	12
Future Outlook	12
Long-Term Goals	12



TABLE OF CONTENTS

TOKENOMICS	13
Token Details	13
Token Distribution	13
ROADMAP	14
Funding Collaboration Partner -YouthBio Therapeutics & Scientific Team	15
LEGAL DISCLAIMER	16
CONTACT DETAILS	17

EXECUTIVE SUMMARY

Neurodegenerative diseases, such as Alzheimer's, Parkinson's, ALS, and Multiple Sclerosis, are among the most devastating and complex medical conditions affecting millions worldwide. These diseases progressively deteriorate the nervous system, leading to cognitive decline, memory loss, impaired motor function, and ultimately, loss of independence.

As life expectancy increases globally, the prevalence of these disorders is expected to rise, creating an urgent need for innovative solutions. The economic and social burden of neurodegenerative diseases is immense, with billions spent annually on healthcare, caregiving, and supportive services. Despite extensive research efforts, current treatments are largely ineffective in reversing disease progression, offering only symptomatic relief. Traditional research funding models, prolonged clinical trial processes, and regulatory barriers have further slowed the development of effective therapies, leaving millions of patients and families with little hope.

The challenge in treating neurodegenerative diseases lies in the complexity of the brain and the difficulty in regenerating damaged neurons. Conventional drug treatments primarily focus on delaying symptoms rather than addressing the root cause of neuronal degeneration. Additionally, funding for research is often dependent on large pharmaceutical companies, government grants, and donations, which can be unpredictable and slow-moving. Many promising breakthroughs in regenerative medicine, gene therapy, and epigenetics remain underfunded, delaying their transition from laboratory research to clinical application.

This is where Alzheimer's Cure Charity Token comes into play!

Alzheimer's Cure Charity Token envisions a DeSci ecosystem where patients, caregivers, scientists, and investors collaborate to drive innovation in neurodegenerative disease research. The project is designed to disrupt this stagnant landscape by introducing a blockchain-powered funding model to accelerate the development of epigenetic gene therapies for neurodegenerative diseases. Built on the Solana network, The Cure token serves as a financial engine that directly funds cutting-edge research aimed at regenerating, repairing, and restoring neurons and brain matter.

ALZHEIMER'S CURE CHARITY TOKEN - AN INTRODUCTION

Getting Results Now in Decentralized Science.
One Token to Rule them All

Alzheimer's Cure Charity Token is a groundbreaking DeSci initiative leveraging blockchain technology to directly fund the development of epigenetic gene therapies for Alzheimer's and other neurodegenerative diseases. Built on the Solana network, The Cure is a utility token designed to drive medical advancements by financing research and accelerating the development of cutting-edge treatments.

By utilizing Yamanaka Factors, a Nobel Prize-winning biotechnology that holds the potential to regenerate neurons, astrocytes, and brain tissue, this initiative aims to revolutionize how these conditions are treated, focusing on actual disease reversal rather than temporary symptom management.

With a mission to fund, develop, and fast-track breakthrough treatments, The Cure focuses on a wide range of neurodegenerative diseases, including Alzheimer's, dementia, Parkinson's, stroke, traumatic brain injury, chronic traumatic encephalopathy (CTE), multiple sclerosis, ALS, and Huntington's disease.

By sequentially addressing each condition, the token's ecosystem will strategically channel funds into research, clinical trials, and innovative therapies, ensuring that life-changing medical solutions reach patients as swiftly as possible. By eliminating reliance on slow-moving traditional funding mechanisms, Alzheimer's Cure Charity Token empowers researchers with the financial resources needed to accelerate breakthroughs and bring real treatments to patients faster than ever before.

Additionally, by bridging the gap between biotechnology and decentralized finance, Alzheimer's Cure Charity Token introduces a new model for medical funding—one that is transparent, efficient, and driven by the collective power of blockchain technology and global community support. Beyond funding, the project aims to build strategic partnerships with leading biotech firms, research institutions, and medical professionals to ensure that discoveries move from laboratory to clinical trials and eventually to real-world treatments.

MISSION

OUR MISSION IS

- To accelerate the development of gene therapies for Alzheimer's and other neurodegenerative diseases using innovative blockchain-based funding.
- To utilize The Cure token as a financial tool to directly support cutting-edge research and clinical trials.
- To harness the power of Yamanaka Factors and epigenetic reprogramming to regenerate, repair, and restore brain function.
- To provide transparent funding mechanisms that empower researchers, scientists, and medical institutions to fast-track breakthroughs.
- To create a global community dedicated to advancing neurodegenerative disease treatments through decentralized finance and biotechnology.

VISION

OUR VISION IS,

- To eradicate neurodegenerative diseases by supporting revolutionary gene therapy innovations.
- To make regenerative medicine accessible to all, ensuring that breakthroughs reach patients swiftly and effectively.
- To establish a sustainable funding ecosystem for medical research, removing reliance on slow-moving traditional funding models.
- To become the leading blockchain-powered platform for financing scientific advancements in neuroscience and biotechnology.
- To build a future where Alzheimer's and related conditions are preventable, treatable, and curable.

ALZHEIMER'S CURE CHARITY TOKEN ECOSYSTEM

The Alzheimer's Ecosystem is a decentralized and transparent financial infrastructure designed to fund groundbreaking research and development for neurodegenerative disease treatments. Built on the Solana blockchain, the ecosystem leverages The Cure, its native utility token, to support scientific advancements, clinical trials, and the development of epigenetic gene therapies for Alzheimer's, Parkinson's, ALS, and other neurological disorders.

At its core, the ecosystem connects research institutions, biotech companies, healthcare professionals, investors, and the global community, creating a sustainable and decentralized funding model. Unlike traditional funding methods, which can be slow and bureaucratic, the Alzheimer's Ecosystem democratizes contributions, enabling direct financial support for cutting-edge neuroscience research.

By integrating blockchain technology with medical innovation, the Alzheimer's Ecosystem fosters a sustainable, ethical, and results-driven approach to tackling some of the world's most challenging neurodegenerative diseases.

OUR APPROACH IN CURING NEURODEGENERATIVE DISEASES

We believe that the key to curing neurodegenerative diseases lies in cutting-edge biotechnology and innovative research. Our approach focuses on harnessing Yamanaka Factors and epigenetic control to reverse cellular aging and restore lost neurological function.

HARNESSING YAMANAKA FACTORS FOR REGENERATIVE THERAPY

Yamanaka Factors, a Nobel Prize-winning discovery, have demonstrated the potential to reset cells to a youthful state. In preclinical studies, they have been shown to reverse aging effects and restore function in damaged brain cells. With three positive studies supporting their effectiveness in Alzheimer's disease, we are actively working toward FDA clinical trials and are already planning human trials in another country.

UNLOCKING THE POWER OF EPIGENETICS

If DNA is the hardware of our biology, then epigenetics functions as the software that determines how our genes are expressed. By reprogramming gene expression, we can rejuvenate brain tissue, potentially reversing neurodegenerative diseases rather than just treating symptoms. This approach provides a groundbreaking pathway toward true neurological restoration.



TARGETED DISEASES: A MISSION TO RESTORE BRAIN HEALTH

The Cure is dedicated to combating a wide range of neurodegenerative diseases that affect millions worldwide. By leveraging cutting-edge biotechnology, the project aims to develop therapies for conditions including

<p>Alzheimer’s Disease & All Forms of Dementia</p> <p>Addressing memory loss, cognitive decline, and neural degeneration.</p>	<p>Parkinson’s Disease</p> <p>Developing treatments to restore motor function and slow disease progression.</p>
<p>Traumatic Brain Injury (TBI) & Stroke</p> <p>Focusing on neuron regeneration and brain tissue repair.</p>	<p>Chronic Traumatic Encephalopathy (CTE)</p> <p>Targeting brain damage caused by repeated head trauma.fr</p>
<p>Multiple Sclerosis (MS)</p> <p>Exploring therapies to repair myelin sheath damage and restore nerve function.</p>	<p>Amyotrophic Lateral Sclerosis (ALS)</p> <p>Advancing research into motor neuron protection and regrowth.</p>
<p>Huntington’s Disease & Other Neurodegenerative Disorders</p> <p>Investigating gene therapies to halt and reverse genetic brain disorders.</p>	

Each of these conditions will be addressed sequentially, with resources allocated to research, development, and clinical trials to ensure maximum impact.

RESEARCH AND DEVELOPMENT: ADVANCING TOWARDS BREAKTHROUGH THERAPIES

The Cure is built on the foundation of scientific excellence and rapid innovation. Our approach focuses on translating groundbreaking discoveries into real-world treatments as swiftly as possible.



CURRENT PROGRESS IN PRECLINICAL RESEARCH

A confidential targeted company has already completed three successful preclinical studies in

Alzheimer's Disease

Demonstrating potential reversal of cognitive decline.

Age-Related Cognitive Decline

Addressing memory loss and brain aging.

With this solid scientific foundation, the project is rapidly advancing towards human clinical trials, setting the stage for a revolutionary shift in neurodegenerative disease treatment.

THE CURE - THE NATIVE UTILITY TOKEN

The Cure is the native utility token driving the Alzheimer's Cure Charity Token ecosystem, providing a decentralized funding mechanism to support research, development, and clinical trials for groundbreaking gene therapies. Built on the Solana blockchain, The Cure ensures secure, transparent, and efficient transactions while enabling community participation in the fight against neurodegenerative diseases.

TOKEN UTILITIES

Through the following utilities, The Cure serves as a critical financial backbone for medical advancements, ensuring continuous progress in treating and potentially curing neurodegenerative diseases

<p>Funding Scientific Research</p> <p>Directly supports the development of gene therapies targeting Alzheimer's and other neurodegenerative diseases.</p>	<p>Staking for Rewards</p> <p>Users can stake The Cure to earn passive rewards while contributing to long-term research funding. 2% a month for token holders will be awarded every month</p>
<p>Access to Exclusive Scientific Reports</p> <p>The Cure holders receive early access to clinical trial updates, data releases, and breakthrough findings.</p>	<p>Charitable Contributions</p> <p>A portion of The Cure transactions is allocated to foundations, patient support programs, and Alzheimer's research initiatives.</p>
<p>Partnership Integrations</p> <p>Facilitates collaborations with biotech firms, research institutions, and pharmaceutical companies to accelerate treatment development.</p>	

A DEFLATIONARY TOKEN BURNING MECHANISM

The Cure incorporates a strategic token-burning model to create a deflationary supply and reward long-term holders while marking key scientific achievements. The following structured burn mechanism ensures that The Cure retains long-term value, incentivizes community engagement, and reinforces trust in the ecosystem's commitment to real-world impact.

TOKEN BURN MECHANISM

Milestone-Based Burns – The Cure tokens will be burned upon major positive catalyst events, such as

Successful data releases from preclinical or clinical trials	Regulatory approvals or significant breakthroughs.	Completion of human clinical trials with positive results.
--	--	--

Burn Amounts Per Event – Depending on the milestone, token burns will range from 1 million to 100 million tokens per event, reducing overall supply and increasing scarcity.

DAILY SELL LIMITS FOR STABILITY

Through the following utilities, The Cure serves as a critical financial backbone for medical advancements, ensuring continuous progress in treating and potentially curing neurodegenerative diseases

Treasury Limit

The project's treasury and creator tokens are restricted to selling a maximum of 5 million tokens per day, ensuring controlled liquidity and long-term sustainability.

Treasury Holdings

Treasury can hold BTC, Solana, USDC and other crypto as core holdings for diversification. This will be relayed in treasury reports.

DONATIONS: DIRECTLY SUPPORTING BREAKTHROUGH RESEARCH

To accelerate the development of epigenetic gene therapies for Alzheimer's and other neurodegenerative diseases, direct funding will be made to YouthBio Therapeutics, a biotech company at the forefront of this groundbreaking research. This private biotech company has registered patents in the US and globally covering their technology. This will provide crucial funding for clinical trials, laboratory advancements, and regulatory approvals, ensuring rapid progress in bringing effective treatments to patients.

HOW DONATIONS WORK?

Donations will be transferred directly to the biotech company's designated wallet in Bitcoin (BTC) or Solana (SOL) to maintain efficiency and transparency.

The recipient company will provide periodic updates on research progress, breakthrough findings, and trial advancements through

Blockchain records for immutable tracking of fund utilization.

Press releases and public reports to keep stakeholders and supporters informed.

This transparent donation model ensures that every contribution directly impacts scientific innovation, helping to fast-track the discovery of life-changing treatments for Alzheimer's and other neurological conditions.

THE FUTURE SCOPE

The Alzheimer's Cure Charity Token project is committed to long-term advancements in epigenetic gene therapies, with a clear roadmap towards human trials, regulatory approvals, and global accessibility. Our vision extends beyond treating neurodegenerative diseases—we aim to revolutionize healthcare by utilizing cellular rejuvenation and regenerative medicine to enhance human longevity and quality of life.

Additionally, with a strong foundation in biotech innovation and blockchain transparency, Alzheimer's Cure Charity Token is set to reshape the future of medical treatments, offering real hope for patients and caregivers across the globe.

FUTURE OUTLOOK

Significant human trial progress is expected by 2025/2026, with transparent updates on

Clinical trial outcomes and efficacy reports. Human clinical trial data is expected in 2025/26 from Australia as well as U.S. FDA ongoing regulatory updates by mid 2025.

Drug development phases and breakthroughs.

Regulatory approvals and safety assessments.

All key developments will be publicly shared via blockchain and press releases, ensuring accountability and trust among stakeholders.

LONG-TERM GOALS

Longevity and Health












By leveraging epigenetic manipulation to regrow, repair, and rejuvenate brain tissues, we aim to extend healthy human lifespan and improve overall cognitive function.

Regulatory Approval


Achieving FDA, EU, and global regulatory clearances is a top priority to ensure that these therapies become widely available to millions of patients worldwide suffering from Alzheimer's, dementia, Parkinson's, and other neurodegenerative conditions.

TOKENOMICS

Token Details

 COIN NAME The Cure	 COIN SYMBOL CURE	 BLOCKCHAIN SOLANA
 TOKEN STANDARD SPL-20	 TOTAL SUPPLY 1 Billion	 DECIMAL 9
 MINTABLE NO	 SUPPLY TYPE CAPPED	 ACCESS TYPE OWNABLE
 VERIFIED SOURCE CODE YES	 BURNABLE YES	

Token Distribution



Phase 1

Foundation & Research

- Establish project fundamentals and partnerships with biotech firms.
- Secure funding for preclinical and early-stage research.
- Conduct additional preclinical studies on Alzheimer's and other neurodegenerative diseases.
- Begin discussions with regulatory agencies for clinical trial approvals.

1

Phase 2

Smart Contract Development & Token Launch

- Develop and audit The Cure coin smart contract on Solana.
- Conduct internal and third-party audits for security and compliance.
- Deploy The Cure coin token on the blockchain.
- Launch private and public token sales.

2

3

Phase 3

Clinical Trials & Token Utility Expansion

- Initiate first-in-human clinical trials for Alzheimer's gene therapy.
- Implement blockchain-based transparency for clinical progress updates.
- Expand token utility for donations, staking, and governance participation.
- Partner with leading biotech companies and regulatory consultants.
- Strengthen engagement with the research community and patient advocacy groups.

4

Phase 4

Global Expansion & Real-World Integration

- Clinical trials towards late-stage approval.
- Seek FDA, EU, and international regulatory clearances.
- Introduce institutional partnerships with hospitals, research centers, and biotech firms.
- Implement large-scale token burns based on successful trial milestones.
- Expand token adoption for healthcare funding and biotech investments.

5

Phase 5

Widespread Adoption & Future Innovations

- Launch approved therapies for Alzheimer's and other neurodegenerative diseases.
- Integrate blockchain-based medical funding models for broader healthcare applications.
- Explore AI-driven diagnostics and personalized treatment strategies.
- Expand research into longevity and other age-related diseases.
- Establish a global ecosystem of biotech and blockchain-driven medical advancements.

ROADMAP

FUNDING COLLABORATION PARTNER

YouthBio Therapeutics & Scientific Team

Our funding collaboration partner, YouthBio Therapeutics (<https://youthbiotx.com/alzheimers>), pioneers epigenetic rejuvenation and longevity therapies, accelerating treatments for Alzheimer's, Progeria, and other neurodegenerative diseases through scientific innovation.



Viet Ly

Founder

Viet is an angel investor and entrepreneur with over twenty five years of biotech experience that spans drug development, equities analysis, fund management, and business development. As an early investor, Viet helped build Genprex, a biotech company developing the first gene therapies for cancer and diabetes, one of which (REQORSA) is undergoing three clinical trials including a Phase 2.

Viet has researched and invested in biotech companies since 2004. He has also been an early investor in Airbnb, SpaceX, and others. Viet is passionate about the global markets, cryptocurrencies, building businesses, emerging technology and biotech.

Viet is a graduate of the University of Washington Foster Business School in 2000, with a Business Administration degree in finance and marketing.

LEGAL DISCLAIMER

NOTE

WE STRONGLY SUGGEST THE READER TO GO THROUGH THE SECTION TITLED “DISCLAIMER OF LIABILITY” COMPLETELY BEFORE PROCEEDING TO READ THE OTHER CONTENTS OF THIS WHITEPAPER ISSUED BY ALZHEIMER’S CURE CHARITY TOKEN.

Any kind of information, predictions, assumptions, and statistics represented in this whitepaper are completely for GENERAL PURPOSES. It is advised that the information accommodated in this whitepaper cannot be understood as a financial, legal, or advisory council. This whitepaper does not lead to an INVITATION TO INVEST and does not organize or promote any type of contractual obligation. If you come across any queries or doubts, we recommend that you seek assistance from an attorney, accountant, or any other deemed fiduciary of your choice. Any reference to external resources or third-party material in the whitepaper is provided for representational purposes only and cannot be understood as any form of approval or endorsement of their information or estimations.

By reading this whitepaper, you agree to absolve ALZHEIMER’S CURE CHARITY TOKEN from any responsibility for any damages arising directly or indirectly from relying on any information provided in this document. Regarding more queries about legislation and regulations concerning cryptocurrency, we highly recommend that you seek counsel from qualified professionals and your attorney, accountant, or trusted fiduciary. When drafting this whitepaper, the utmost care and diligence were exercised to ensure the integrity of the facts and statements mentioned in the document. However, ALZHEIMER’S CURE CHARITY TOKEN does not guarantee the complete accuracy or legal relevancy of the information presented in this whitepaper.

By reviewing and seeking information about ALZHEIMER’S CURE CHARITY TOKEN, the reviewer confesses that they have read, understood, agreed, and embraced all the terms and conditions mentioned in the section labeled “DISCLAIMER.”



Reach out to us through any one of the following
platforms

www.alzcuretoken.com